UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria

UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria

The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Brunschwig, C, Lawrence, N, Taylor, D, Abay, E, Njoroge, M, Basarab, GS, Le Manach, C, Paquet, T, Cabrera, D, Nchinda, AT, de Kock, C, Wiesner, L, Denti, P, Waterson, D, Blasco, B, Leroy, D, Witty, MJ, Donini, C, Duffy, J, Wittlin, S, White, KL, Charman, SA, Jiménez-Díaz, MB, Angulo-Barturen, I, Herreros, E, Gamo, FJ, Rochford, R, Mancama, D, Coetzer, TL, van der Watt, ME, Reader, J, Birkholtz, L-M, Marsh, KC, Solapure, SM, Vanaerschot, M, Fidock, DA, Fish, PV, Siegl, P, Smith, DA, Wirjanata, G, Noviyanti, R, Price, RN, Marfurt, J, Silue, KD, Street, LJ, Chibale, K
Materialtyp: Journal article
Språk:English
Publicerad: American Society for Microbiology 2018

Liknande verk